| Ytd | -32.91% | |
| 1y | 29.03% |
| Open | 3.02 | Prev Close | 3.10 | Low | 3.02 | High | 3.34 | Mkt Cap | 26.69M |
| Vol | 34.83K | Avg Vol | 31.27K | EPS | -1.00 | P/E | N/A | Forward P/E | -0.72 |
| Beta | -0.23 | Short Ratio | 0.75 | Inst. Own | 9.90% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-18 | 50-d Avg | 3.88 | 200-d Avg | 4.48 | 1yr Est | 11.56 |
EVAX News
New preclinical data will guide antigen selection for a broadly protective cytomegalovirus vaccine c
COPENHAGEN, Denmark, July 1, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio
EVX-04 is successfully expressed and secreted in human cells enabling immune recognition and activat
Data will reflect the functional characterization of EVX-04Poster presentation on June 13, 2026COPEN
Evaxion Biotech (NASDAQ:EVAX) reported quarterly losses of $(0.01) per share which beat the analyst
Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel va
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Evaxion (NASDAQ:EVAX) with a Bu
Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vac
Data analysis conducted in collaboration with a leading academic medical center shows that AI‑Immuno
EVX-01 is a personalized cancer vaccine currently being evaluated as a treatment for advanced melano
Lake Street analyst Thomas Flaten maintains Evaxion (NASDAQ:EVAX) with a Buy and lowers the price
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Evaxion (NASDAQ:EVAX) with a Bu
Evaxion Biotech (NASDAQ:EVAX) reported quarterly losses of $(0.02) per share which beat the analyst
Merck declines its option on Evaxion's EVX-B2 gonorrhea vaccine, leaving global rights with Evax
Designed with our proprietary AI-Immunology™ platform based on patient sequencing data, EVX-04 targe
Evaxion's AI-Immunology™ platform has discovered novel CMV antigens that significantly reduce vi
Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in deve
Evaxion Biotech (NASDAQ:EVAX) reported quarterly earnings of $0.01 per share which beat the analyst
Evaxion introduces EVX-04, a novel vaccine candidate targeting multiple non-conventional ERV tumor a
Edward Jones analyst Soumit Roy initiates coverage on Evaxion (NASDAQ:EVAX) with a Buy rating and
Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in dev
Lake Street analyst Thomas Flaten maintains Evaxion (NASDAQ:EVAX) with a Buy and raises the price
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Evaxion (NASDAQ:EVAX) with a Bu
Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in deve
Presentation will cover two-year clinical efficacy, immunogenicity and safety dataData will be prese
Gainers Enanta Pharma (NASDAQ: ENTA) stock rose 15.6% to $9.13 during Friday's after-market ses
Gainers PepGen (NASDAQ: PEPG) stock rose 114.3% to $5.7 during Thursday's regular session. The
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Evaxion (NASDAQ: EVAX) with a Bu
Gainers PepGen (NASDAQ: PEPG) shares rose 141.0% to $6.41 during Thursday's pre-market session.
OPEN: 11% | Opendoor shares are trading higher after Jane Street Group disclosed in a 13G filing tha
Evaxion and the European Investment Bank (EIB) have finalized a debt settlement agreement of €3.5 mi
https://www.sciencedirect.com/science/article/pii/S0264410X25007133
Initial computational analysis demonstrated that Evaxion's AI-Immunology™ platform can identify
Evaxion awarded a grant from the Gates FoundationGrant funds research aimed at ultimately eradicatin